I read with great interest the well-written manuscript by Ghaemian and colleagues 1 regarding the benefits of implementing a remote ischemic preconditioning protocol before percutaneous coronary revascularization. Post-procedural myocardial injury occurs in approximately one-third of patients undergoing percutaneous coronary intervention (PCI) and has been found to adversely affect prognosis; therefore, the need for cardioprotection during these procedures is evident. In the setting of anticipated myocardial ischemia, the utilization of an intrinsic cardioprotective mechanism, such as remote ischemic preconditioning, is a low-cost strategy with significant benefits. The findings of Ghaemian and colleagues 1 seem to concur with data from several recent studies, including our recently presented data. [2] [3] [4] Nevertheless, some evidence presented in this study merits further clarification. According to Table  3 , patients in the rIPC group had significantly higher troponin T levels compared to controls at 12 and 24 hours post-PCI (0.051 AE 0.126 vs. 0.013 AE 0.012 ng mL À1 ; p ¼ 0.07 and 0.063 AE 0.108 vs. 0.016 AE 0.016 ng mL À1 ; p ¼ 0.009, respectively). In fact, since only 5 patients in the rIPC group had troponin T levels above 0.03 ng mL À1 , compared to 16 patients in the control group, one could hypothesize that only patients in the rIPC groups would satisfy the criteria for a PCI-related myocardial infarction. Accordingly, if the study results are not erroneously presented in Table  3 , the increased troponin T levels in the remote IPC group, seem to be more consistent with the findings of Prasad and colleagues 5 and Iliodromitis and colleagues 6 who observed increased myocardial injury with rIPC, suggesting that a more accurate conclusion of the study would be perhaps contradictory to the one presented by the authors.
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